Human Longevity Inc. Unleashes Power of Whole-Genome Sequencing to Unlock Keys to Healthy Aging; Research May Lead to New Clinical Laboratory Tests

Human genome pioneer J. Craig Venter’s newest project seeks to ‘change the way medicine is practiced’ by creating genomic-based medicine model With little fanfare or public notice, a start-up company in San Diego is busy sequencing the largest number of whole human genome sequences in the world. The knowledge expected to result from this effort promises to revolutionize healthcare, as well as clinical laboratory testing. Human Longevity Inc. (HLI) is a genomics and cell therapy company that...

Google Takes First Steps to Create World’s Largest Human Genome Database as Part of Wider Strategy to Become a Major Player in Healthcare ‘Big Data’

Google’s goal is to build a genomics database to facilitate early diagnosis and prevention of life-threatening diseases; may give pathologists a new diagnostic tool Google (NASDAQ: GOOG) is preparing to build a human genome database that it says may become the world’s biggest. The company plans to also assemble other medical information, including clinical laboratory test data, as it pursues plans to become a player in the market for healthcare Big Data. This work will be done by Google X Life...

J. Craig Venter Joins Race to Crack the Puzzle of Human Aging with New Company That Aims to Sequence 100,000 Human Genomes Yearly

Big Data will play major role as Venter’s team sets out to build world’s largest database of human genotypes, microbiomes and phenotypes For the second time in recent months, another prominent figure has declared his intention to crack the code of human aging. This time it is scientist and entrepreneur J. Craig Venter, Ph.D., known for his role in sequencing the first whole human genome. Venter will pursue this goal through a brand new company he launched, called Human Longevity, Inc. (HLI),...

Clinical Laboratory Company Quest Diagnostics Agrees to Acquire Celera Corp. for $657 Million

Celera is not a medical laboratory, but develops biomarkers and molecular diagnostics tests For the second time since the New Year, Quest Diagnostics Incorporated (NYSE:DGX) has announced an acquisition. Last Friday, Quest Diagnostics said it had agreed to purchase Celera Corp. (NASDAQ:CRA) for a purchase price that Reuters reported to be $657 million. What makes this acquisition different from those typically done by Quest Diagnostics and its major competitor, Laboratory Corporation of...